Difference between revisions of "Idecabtagene vicleucel (Abecma)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "www.ncbi.nlm.nih.gov/pubmed" to "pubmed.ncbi.nlm.nih.gov") |
m |
||
| Line 1: | Line 1: | ||
| + | ==Mechanism of action== | ||
Anti-BCMA CAR T-cells. | Anti-BCMA CAR T-cells. | ||
| − | == | + | ==Diseases for which it is used== |
| − | + | *[[Multiple myeloma]] | |
# '''CRB-401:''' Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019 May 2;380(18):1726-1737. [https://www.nejm.org/doi/full/10.1056/NEJMoa1817226 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31042825 PubMed] | # '''CRB-401:''' Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019 May 2;380(18):1726-1737. [https://www.nejm.org/doi/full/10.1056/NEJMoa1817226 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31042825 PubMed] | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *3/26/2021: Approved for the treatment of adult patients with relapsed or refractory [[multiple myeloma]] after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' bb2121 | ||
| + | *'''Generic name:''' ide-cel | ||
| + | *'''Brand name:''' Abecma | ||
[[Category:Chimeric antigen receptor T-cells]] | [[Category:Chimeric antigen receptor T-cells]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | [[Category: | + | [[Category:Multiple myeloma medications]] |
| + | [[Category:FDA approved in 2021]] | ||
Revision as of 00:29, 30 March 2021
Mechanism of action
Anti-BCMA CAR T-cells.
Diseases for which it is used
- CRB-401: Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019 May 2;380(18):1726-1737. link to original article PubMed
History of changes in FDA indication
- 3/26/2021: Approved for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
Also known as
- Code name: bb2121
- Generic name: ide-cel
- Brand name: Abecma